259 related articles for article (PubMed ID: 31070270)
1. Exendin-4 analogs in insulinoma theranostics.
Jansen TJP; van Lith SAM; Boss M; Brom M; Joosten L; Béhé M; Buitinga M; Gotthardt M
J Labelled Comp Radiopharm; 2019 Aug; 62(10):656-672. PubMed ID: 31070270
[TBL] [Abstract][Full Text] [Related]
2. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys
Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L
Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984
[TBL] [Abstract][Full Text] [Related]
3.
Sakaki K; Murakami T; Fujimoto H; Shimizu Y; Miyake KK; Otani D; Kiyobayashi S; Okada T; Fujimoto M; Hakata T; Yamauchi I; Shimada K; Shimizu H; Nagai K; Nakamoto Y; Inagaki N
Front Endocrinol (Lausanne); 2023; 14():1245573. PubMed ID: 37720533
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
5. Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients.
Buitinga M; Jansen T; van der Kroon I; Woliner-van der Weg W; Boss M; Janssen M; Aarntzen E; Béhé M; Wild D; Visser E; Brom M; Gotthardt M
J Nucl Med; 2019 Jun; 60(6):812-816. PubMed ID: 30504139
[TBL] [Abstract][Full Text] [Related]
6. Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis.
Shah R; Garg R; Majmundar M; Purandare N; Malhotra G; Patil V; Ramteke-Jadhav S; Lila A; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2021 Aug; 95(2):354-364. PubMed ID: 33386617
[TBL] [Abstract][Full Text] [Related]
7. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
8. Development of
Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
10. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
12. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.
Eriksson O; Velikyan I; Selvaraju RK; Kandeel F; Johansson L; Antoni G; Eriksson B; Sörensen J; Korsgren O
J Clin Endocrinol Metab; 2014 May; 99(5):1519-24. PubMed ID: 24512490
[TBL] [Abstract][Full Text] [Related]
13. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
[TBL] [Abstract][Full Text] [Related]
14. Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.
Zhang M; Jacobson O; Kiesewetter DO; Ma Y; Wang Z; Lang L; Tang L; Kang F; Deng H; Yang W; Niu G; Wang J; Chen X
Bioconjug Chem; 2019 Jun; 30(6):1745-1753. PubMed ID: 31181890
[TBL] [Abstract][Full Text] [Related]
15. Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.
Antwi K; Fani M; Nicolas G; Rottenburger C; Heye T; Reubi JC; Gloor B; Christ E; Wild D
J Nucl Med; 2015 Jul; 56(7):1075-8. PubMed ID: 25999434
[TBL] [Abstract][Full Text] [Related]
16. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
17. Development of an
Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
[TBL] [Abstract][Full Text] [Related]
18. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
19. Preparation of [
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Nucl Med Biol; 2019; 78-79():31-40. PubMed ID: 31731177
[TBL] [Abstract][Full Text] [Related]
20. Imaging of Insulinoma by Targeting Glucagonlike Peptide-1 Receptor.
Luo Y; Chen X
PET Clin; 2021 Apr; 16(2):205-217. PubMed ID: 33589387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
